LONDON, July 7 — The mechanics here are straightforward on paper: the NHS performs genetic testing for BRCA mutations through regional genetics services, and in 2024 it expanded testing to include all women with breast cancer under 50. The catch is that preventive testing for at-risk relatives like Ellie Sullivan remains subject to strict criteria. The numbers tell a sharper story.
Studies indicate that only about 30% of eligible individuals in the UK are referred for genetic counseling. As of 2026, there is no centralized data on how many women are denied testing outright, which makes it difficult to track where the system is failing most.
Follow the money, follow the backlogs
The NHS has faced backlogs due to staffing shortages and funding constraints. These are not abstract problems. Regional genetics services require specialist clinical geneticists and genetic counselors, a workforce that has not kept pace with demand.
The strict criteria for preventive testing are the direct result of that constraint. Ellie’s case, reported by Leah Hardy in July 2026, exemplifies how women with a family history can fall through the cracks.
The 2024 expansion was a meaningful step for women diagnosed under 50, but it did not address the bottleneck upstream.
Why the criteria matter
The NHS Genomic Medicine Service sets the clinical guidelines. For a woman without cancer but with a family history, the criteria for preventive BRCA testing typically require a certain probability threshold based on the number and type of affected relatives. The result is a gap between what is technically possible and what is actually offered.
Women who meet the criteria for referral may still not receive it because their GP or specialist does not initiate the process. And even when referral happens, regional genetics services can have waiting lists that stretch for months.
The backlogs compound the problem: a woman who waits months for genetic counseling may already be past the point where preventive measures would have been most effective.
What to watch next
The key question is whether the NHS Genomic Medicine Service will update its preventive testing criteria to match the expanded testing for diagnosed patients. If the 2024 expansion for women under 50 with breast cancer generates more data on BRCA prevalence in that population, it may pressure the system to loosen the criteria for relatives. But that depends on the NHS addressing the staffing shortages and funding constraints that created the backlogs in the first place.
The Ellie Sullivan case has put a face on the numbers. Without centralized data on how many women are denied testing, the true scale of the problem remains unknown.
What is known is that only about 30% of eligible individuals receive a referral, and that the system’s capacity has not kept pace with its own policy expansions. The mechanics of genetic testing in the UK are sound in theory; the execution is where the cracks appear. Consult your doctor for medical advice.
